Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19543667 | 0.90 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL17708256 | 0.90 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL23964464 | 0.87 | ALDH1A1 (0.32) | MAPK1ALDH1A1 | |
| SCHEMBL12555908 | 0.83 | TSHR (0.33) | MAPK1ALDH1A1TSHRTDP1 | |
| SCHEMBL19542925 | 0.83 | TSHR (0.33) | MAPK1ALDH1A1TSHRTDP1 | |
| SCHEMBL13538680 | 0.83 | TSHR (0.33) | MAPK1ALDH1A1TSHRTDP1 | |
| SCHEMBL23958969 | 0.83 | — | — | |
| SCHEMBL14213292 | 0.81 | MAPK1 (0.36) | MAPK1ALDH1A1TSHR | |
| SCHEMBL19655069 | 0.81 | ALDH1A1 (0.33) | MAPK1ALDH1A1 | |
| SCHEMBL16883925 | 0.81 | MAPK1 (0.36) | MAPK1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4298182-B1 | DIELECTRIC THERMAL MANAGEMENT FLUIDS AND METHODS FOR USING THEM | CASTROL LTD (GB) | 2025-06-04 | — | — | EP | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240191119-A1 | Dielectric Thermal Management Fluids and Methods for Using Them | CASTROL LIMITED (GB) | 2024-06-13 | — | — | US | disclosed |
| US-20230241217-A1 | HYDROGEL IRRADIATION | ASCENDIS PHARMA A/S (DK) | 2023-08-03 | — | — | US | disclosed |
| EP-3534214-B1 | PROCESS CARTRIDGE AND IMAGE-FORMING APPARATUS | CANON KK (JP) | 2022-02-16 | — | — | EP | disclosed |
| US-10501499-B2 | Peptides derived from viral proteins for use as immunogens and dosage reactants | BIONOR IMMUNO AS (NO) | 2019-12-10 | — | — | US | disclosed |
| EP-3534215-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3534214-A1 | PROCESS CARTRIDGE AND IMAGE-FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-9983456-B2 | Light control film | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9855340-B2 | Hydrogel prodrugs | ASCENDIS PHARMA A/S (DK) | 2018-01-02 | — | — | US | disclosed |
| US-8681418-B2 | Light control film | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-8570642-B2 | Light control film | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8541448-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120314276-A1 | LIGHT CONTROL FILM | GAUZY LTD (IL) | 2012-12-13 | — | — | US | disclosed |
| US-20120307348-A1 | LIGHT CONTROL FILM | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120263670-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8138272-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110217546-A1 | LIGHT CONTROL FILM | GAUZY LTD (IL) | 2011-09-08 | — | — | US | disclosed |
| US-20110143131-A1 | LIGHT CONTROL FILM | GAUZY LTD (IL) | 2011-06-16 | — | — | US | disclosed |
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | PIGO, MANBA, OAT | MAPK1 3922/4885ALDH1A1 174/4885TSHR 2205/4885 |
| US-20120263670-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | MAPK1 2602/4885ALDH1A1 1732/4885TSHR 688/4885 |
| US-20230241217-A1 | HYDROGEL IRRADIATION | H1-0, H1-2, H1-3 | MAPK1 3570/4885ALDH1A1 307/4885TSHR 1072/4885 |
| US-10501499-B2 | Peptides derived from viral proteins for use as immunogens and dosage reactants | HAVCR2, CXCL10, CCL5 | MAPK1 2384/4885ALDH1A1 3747/4885TSHR 3610/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | MAPK1 2648/4885ALDH1A1 2512/4885TSHR 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.